Tid Tittel Kategori Vedlegg
20.08.2026
15:22
 Nykode Therapeutics Receives New U.S. Patent Strengthening Intellectual Property Protection for its fully individualized VB10.NEO cancer vaccine program -
1
06.08.2026
20:05
 Nykode Therapeutics - Grant of share options INSIDEHANDEL INS
1
04.08.2026
22:15
 Nykode Therapeutics - update on expected timeline for pending tax appeal - -
22.07.2026
14:00
 Nykode Therapeutics Presents Comprehensive Preclinical Data, Optimized Manufacturing, and Durable Clinical Immunogenicity for their Individualized Neoantigen Therapy VB10.NEO -
1
27.05.2026
07:00
 Nykode Therapeutics - Quarterly Report Q1 2026 RAPPORT RAP
1
18.05.2026
11:34
 Nykode Therapeutics – Invitation to Q1 2026 Financial Results Presentation -
1
13.05.2026
11:15
 Nykode Therapeutics ASA - Minutes of Annual General Meeting -
1
07.05.2026
13:54
 Nykode Therapeutics Doses First Patient in Abili-T Phase II Randomized Trial evaluating Abi-suva in HPV16-Positive, PD-L1-Positive Recurrent or Metastatic Head and Neck Cancer Patients -
1
30.04.2026
08:30
 Nykode Therapeutics Presents AI-Powered Immunotherapy Design Capabilities at BioPharma Drug Discovery Nexus 2026 -
1
21.04.2026
08:30
 Nykode Therapeutics ASA - Notice of Annual General Meeting -
1
20.04.2026
12:00
 Nykode Therapeutics Presents Additional Immunogenicity Data from VB-C-03 Trial at the 2026 American Association for Cancer Research (AACR) Annual Meeting -
1
17.04.2026
07:30
 Nykode Therapeutics - Annual Report 2025 RAPPORT RAP
2
20.03.2026
14:45
 Nykode Therapeutics Highlights Robust Immunogenicity and Promising Clinical Activity for Abi-Suva at ICHNO 2026 -
1
18.03.2026
08:30
 Nykode Therapeutics Announces Upcoming Presentations at AACR 2026 and NextGen Biomed 2026 -
1
09.03.2026
08:30
 Nykode Therapeutics to Present at DNB Carnegie Conference on March 10, 2026 -
1
03.03.2026
08:40
 Nykode Therapeutics to Present New Data and Participate in Panel Discussion at the 9th Annual Antigen-Specific Immune Tolerance Summit (ASIT) -
1
25.02.2026
07:00
 Nykode Therapeutics - Quarterly Report Q4 2025 RAPPORT RAP
2
24.02.2026
11:45
 Nykode Therapeutics Announces New Interim Data from the VB-C-03 Trial Showing Encouraging Anti-Tumor Activity and Tolerability of Abi-suva (VB10.16) -
1
11.02.2026
13:45
 Nykode Therapeutics – Invitation to Q4 2025 Financial Results Presentation -
1
30.01.2026
22:44
 Nykode Therapeutics - Grant of share options INSIDEHANDEL INS
1
21.01.2026
11:55
 Nykode Therapeutics ASA - Minutes of Extraordinary General Meeting -
1
19.12.2025
14:45
 Nykode Therapeutics to Present Interim Data from the VB-C-03 trial at the 10th International Congress on Innovative Approaches in Head & Neck Oncology (ICHNO) on March 20, 2026 -
1
18.12.2025
07:00
 Nykode Therapeutics ASA - Notice of Extraordinary General Meeting -
1
18.12.2025
07:00
 Nykode Therapeutics Strengthens Board with the Nomination of Dr. Barbara Krebs-Pohl as New Chair of the Board and Dr. John Beadle as Board Member -
1
24.11.2025
16:40
 Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider INSIDEHANDEL INS
1